You’re Lean, Fit and Your Cholesterol Is High.
How Worried Should You Be?

LDL cholesterol, or LDL-C, measures cholesterol carried in the LDL fraction. Non-HDL-C subtracts HDL-C from total cholesterol and captures cholesterol across a broader group of potentially atherogenic particles. ApoB measures a structural protein: each circulating atherogenic particle carries one apoB molecule, making its concentration a practical proxy for particle number. These tests overlap substantially without being interchangeable.^[2]

Discordance is where the extra test becomes useful

When LDL-C and apoB suggest different levels of risk, that is called discordance. In a UK Biobank analysis of roughly 294,000 adults, apoB added information beyond LDL-C and non-HDL-C. People within the same LDL-C band had different event rates when their apoB differed substantially. This was observational evidence; it does not prove that treating to an apoB target is superior to every LDL-based strategy.^[2]

Lp(a) answers a separate question

Lipoprotein(a), or Lp(a), is a largely inherited lipoprotein-related risk factor. It is not another name for LDL-C, and a lean physique does not tell you its level. Current US guidance recommends measuring it at least once in adulthood. A high result can strengthen the case for carefully managing other modifiable risks; lifestyle changes usually have little effect on Lp(a) itself.^[1][16]

Keep the laboratory’s units attached to the result. Lp(a) may be reported in mg/dL or nmol/L; the two cannot be reliably interchanged using one universal conversion factor. Likewise, an attractive HDL-C value or low triglycerides should not be treated as a mathematical cancellation of elevated atherogenic particles. The complete pattern is more informative than selecting the most reassuring number.^[1][2][16]

Age weighs heavily in short-term cardiovascular risk. A young adult can have few events expected over the next decade while accumulating exposure that matters later. In a pooled cohort of 18,288 people, cumulative LDL-C exposure from young adulthood through middle age was associated with later coronary heart disease even after accounting for the midlife LDL-C measurement. A single current result does not reconstruct the preceding decades.^[3]

Genetic evidence points in the same direction: lifelong exposure to lower LDL-C is associated with substantially lower coronary risk. However, being born with an LDL-lowering variant is not equivalent to starting a drug at age 30, 50 or 70. Genetics supports the importance of duration; it does not supply an exact promised benefit for your next prescription.^[4]

The practical implication is to pay attention to a persistent pattern while there is time to act. Family history, smoking, blood pressure, diabetes, kidney disease and prior cardiovascular disease all change the discussion. So do treatment burden and preferences. The current guideline uses PREVENT estimates of both ten- and thirty-year risk in appropriate adults rather than making fitness the deciding variable.^[1]

A coronary artery calcium scan detects calcified coronary plaque. A score of zero can be reassuring and help resolve uncertain prevention decisions in an appropriate patient. It does not demonstrate the absence of all plaque, exclude every cause of chest symptoms, or guarantee safety through decades of continued exposure.^[1][5]

Age matters here, too. In a study of symptomatic patients undergoing coronary CT angiography, obstructive disease was more likely to occur without detectable calcium in younger patients than in older patients. That finding explains a limitation of the test; it is not a reason to order advanced imaging indiscriminately in young lifters.^[5]

A useful question is, “Would this scan change a treatment decision?” A less useful one is, “Can this scan give me permission to ignore my lipids?” For new chest pressure, unexplained breathlessness, fainting or other concerning symptoms, clinical evaluation takes priority over interpreting a screening number.

The TRAVERSE trial provides meaningful reassurance within a defined setting. It randomized 5,246 men aged 45–80 with symptoms, repeatedly low testosterone and existing or elevated cardiovascular risk to testosterone gel or placebo. Gel was adjusted toward a physiological testosterone range. Major cardiovascular events occurred in 7.0% versus 7.3%; the hazard ratio was 0.96 (95% CI 0.78–1.17), meeting noninferiority criteria.^[8]

TRAVERSE did not test bodybuilding stacks, sustained supraphysiologic exposure, every formulation, or decades of use. Atrial fibrillation, acute kidney injury and pulmonary embolism occurred more often in the testosterone group. Noninferiority for the primary endpoint should not be translated into “nothing to monitor.”^[8]

The FDA’s 2025 labeling action removed the boxed-warning language about increased cardiovascular outcomes while adding or strengthening blood-pressure warnings. Further changes were requested in June 2026. These regulatory updates concern testosterone products and their clinical use; they do not validate untested performance-enhancement regimens.^[9][10]

In HAARLEM, lipids and blood pressure worsened during androgen use and returned toward baseline after cessation. That is encouraging about reversibility of the measured markers, but the study was not designed to prove long-term event safety. A separate cross-sectional study of 140 male weightlifters associated long-term AAS exposure with impaired cardiac function and greater coronary plaque burden. Confounding remains possible, and the design cannot establish an individual’s fate.^[6][7]

For a PED user, a lipid-lowering drug should therefore be viewed as addressing one component of risk. A better LDL-C result is not evidence that blood pressure, cardiac remodeling, arrhythmia risk or every effect of the underlying exposure has also been neutralized. An honest history of compounds and timing makes the clinical assessment more useful.

Diet still matters when you are already lean

Being weight-stable does not mean food choices have no effect on lipids. A six-month randomized study tested a portfolio emphasizing nuts, soy protein, viscous fiber and plant sterols against low-saturated-fat dietary advice. LDL-C fell more with both portfolio strategies. This demonstrates a modifiable lipid response without making weight loss the central intervention.^[11]

That is a useful option to discuss, not a claim that every person can solve severe or inherited dyslipidemia with a menu change. The relevant follow-up is the actual response on repeat testing and whether it is sufficient for the person’s risk. Food quality and medication can contribute to the same goal.

Statins have an unusually deep outcome evidence base

An individual-participant meta-analysis of 27 randomized trials found about a 21% reduction in major vascular events per 1 mmol/L (approximately 38.7 mg/dL) LDL-C reduction: rate ratio 0.79, 95% CI 0.77–0.81. Absolute benefit depended on baseline risk. This is evidence about clinical events, not simply making a lab report look better.^[12]

Potential adverse effects still deserve attention. Muscle adverse effects and a small increase in diabetes diagnoses can matter in treatment selection and follow-up. Symptoms should be assessed rather than dismissed or automatically attributed to a drug. Choosing an agent, intensity or alternative is a clinical decision; an athlete’s priorities belong in that conversation.^[12]

Nonstatins have distinct mechanisms and distinct trials

Ezetimibe reduces intestinal cholesterol absorption. Bempedoic acid inhibits ATP citrate lyase in cholesterol synthesis. PCSK9 monoclonal antibodies such as evolocumab increase LDL-receptor availability by blocking PCSK9-mediated receptor degradation. Different entry points can produce additional LDL lowering; whether a particular intervention reduces events still requires outcome evidence.^[13][15][17]

Safety also differs. IMPROVE-IT reported similar prespecified muscle, hepatic and gallbladder adverse effects between groups. CLEAR Outcomes found more gout and gallstones with bempedoic acid; FOURIER found more injection-site reactions with evolocumab. These trials support options for appropriate patients, not a recommendation that every lean person with an elevated result needs the same treatment.^[13][14][15]

The bempedoic-acid label also warns about tendon rupture and relevant drug interactions—particularly worth discussing in a training population.^[17]

A reduction in a composite endpoint is also not automatically a demonstrated survival benefit. CLEAR Outcomes did not show a significant reduction in cardiovascular or all-cause death. Read the endpoint before repeating a headline—and keep established disease populations separate from otherwise healthy younger lifters.^[14]

Relative effects can sound impressive while concealing how much the starting risk matters. An identical proportional reduction prevents more events when more events would otherwise occur. The time horizon matters just as much: a two-year result and a thirty-year prevention question are not interchangeable.

Bring a trend and a question to the appointment

A productive assessment starts with dated lipid results, family history, blood pressure and a complete medication, supplement and PED history. Include whether results were collected during use, after a change, or after stopping. A repeat measurement and evaluation of possible secondary causes may change the interpretation of one unusual panel.

Ask what additional information would change the plan: apoB, Lp(a), a risk estimate, selected imaging, or testing directed by the medical history. Also ask what response will count as sufficient, when to reassess, and which symptoms or adverse effects to report. The objective is an agreed prevention plan, not the longest possible list of tests.

The conclusion: preserve the benefits of fitness and address the remaining risk

You do not need to choose between valuing performance and caring about cardiovascular prevention. Training, body composition, blood pressure and atherogenic lipoproteins can all matter at once. ApoB can clarify an apparently reassuring panel; Lp(a) can reveal inherited risk; a zero calcium score has a defined role; and clinical trial results help distinguish a promising mechanism from fewer cardiovascular events.

For readers using anabolic compounds, the central evidence boundary is especially important: physiological testosterone replacement and supraphysiologic AAS exposure cannot share one blanket safety conclusion. The goal is to make your long-term cardiovascular health as deliberate as your training.